Mechanisms of resistance to bruton’s tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways [PDF]
Annals of HematologyIt is widely acknowledged that B-cell lymphoma represent a significant threat to human health, and Bruton Tyrosine Kinase inhibitors (BTKi) have been shown to exhibit superior clinical efficacy and safety in comparison to conventional chemotherapy and ...
Xinyu Dong +10 more
doaj +2 more sources
BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies
Blood ReviewsTargeted therapies, consisting of Bruton tyrosine kinase inhibitors (BTKis) or BCL-2 inhibitors, are the mainstay of contemporary treatments for chronic lymphocytic leukemia (CLL). The most common adverse effects (AEs) of BTKis are fatigue, bruising, infection, hematological and cardiovascular AEs.
Michael G Fradley
exaly +4 more sources
Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia [PDF]
eJHaemIntroduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman +2 more
doaj +2 more sources
Zanubrutinib-Induced Acneiform Rash in a Patient With Waldenstrom’s Macroglobulinemia [PDF]
Case Reports in MedicineWaldenström’s macroglobulinemia is a rare lymphoproliferative disorder that can be treated with Bruton’s Tyrosine Kinase inhibitors (BTKi), including zanubrutinib.
Silvia Robuffo +6 more
doaj +2 more sources
RESEARCH ON COHORT OF PATIENTS RELAPSED ON BRUTON TYROSINE KINASE INHIBITORS (BTKI) [PDF]
Hematological Oncology, 2023 Lin Dai +11 more
openalex +2 more sources
Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis [PDF]
Blood Advances, 2021 Elizabeth Brém, Susan O’Brien
openalex +4 more sources
Back from (BTKi) holiday [PDF]
Blood AdvancesDanielle M. Brander, Andrea Sitlinger
openalex +2 more sources
Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe. [PDF]
CardiooncologyAdvances in understanding the biology of chronic lymphocytic leukaemia (CLL) translated into revolutionary treatments with improved survival outcomes.
Aurer I +13 more
europepmc +3 more sources
Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]
CureusNaseem A +3 more
europepmc +3 more sources